{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:01:13Z","timestamp":1791169273822,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.clim.2005.08.006","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T13:03:55Z","timestamp":1127221435000},"page":"207-213","source":"Crossref","is-referenced-by-count":111,"title":["The therapeutic potential of anti-CD20"],"prefix":"10.1016","volume":"117","author":[{"given":"Robert","family":"Eisenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. John","family":"Looney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar759","article-title":"SLE\u2014Rituximab in lupus","volume":"5","author":"Eisenberg","year":"2003","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib3","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.clim.2005.08.006_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.61.10.863","article-title":"Treating human autoimmune disease by depleting B cells","volume":"61","author":"Looney","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0093-7754(03)00239-2","article-title":"Rituximab in B-cell chronic lymphocytic leukemia","volume":"30","author":"Lin","year":"2003","journal-title":"Semin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2005.08.006_bib7","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1093\/rheumatology\/keh618","article-title":"B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis","volume":"44","author":"Looney","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2005.08.006_bib8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1186\/ar1738","article-title":"B cell targeted therapies","volume":"7","author":"Keystone","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2005.08.006_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr. Dir. Autoimmun"},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chambers","year":"2005","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0369-8114(03)00051-8","article-title":"Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents","volume":"52","author":"Bosly","year":"2004","journal-title":"Pathol. Biol. (Paris)"},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2005.08.006_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","article-title":"Rituximab: expanding role in therapy for lymphomas and autoimmune diseases","volume":"55","author":"Rastetter","year":"2004","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1073\/pnas.85.1.208","article-title":"Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes","volume":"85","author":"Tedder","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.clim.2005.08.006_bib16","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","article-title":"Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure","volume":"99","author":"Polyak","year":"2002","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clim.2005.08.006_bib17","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1016\/S0021-9258(18)60461-2","article-title":"Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C","volume":"264","author":"Valentine","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.clim.2005.08.006_bib18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4049\/jimmunol.151.1.71","article-title":"Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. Evidence for involvement of calcium\/calmodulin-dependent protein kinase II","volume":"151","author":"Genot","year":"1993","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.clim.2005.08.006_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02786425","article-title":"B cell maturation and selection at the marrow-periphery interface","volume":"17","author":"Cancro","year":"1998","journal-title":"Immunol. Res."},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib21","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","article-title":"Phenotypic difference of normal plasma cells from mature myeloma cells","volume":"81","author":"Harada","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"J. Immunother."},{"issue":"12","key":"10.1016\/j.clim.2005.08.006_bib23","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.4049\/jimmunol.141.12.4388","article-title":"Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19","volume":"141","author":"Tedder","year":"1988","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002510050412","article-title":"Mice carrying a CD20 gene disruption","volume":"48","author":"O'Keefe","year":"1998","journal-title":"Immunogenetics"},{"issue":"5","key":"10.1016\/j.clim.2005.08.006_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2005.08.006_bib27","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.174.7.4389","article-title":"The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice","volume":"174","author":"Hamaguchi","year":"2005","journal-title":"J. Immunol."},{"issue":"5 Suppl. 14","key":"10.1016\/j.clim.2005.08.006_bib28","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin. Oncol."},{"issue":"6 Suppl. 12","key":"10.1016\/j.clim.2005.08.006_bib29","first-page":"9","article-title":"Rituximab: an insider's historical perspective","volume":"27","author":"Grillo-Lopez","year":"2000","journal-title":"Semin. Oncol."},{"issue":"6 Suppl. 12","key":"10.1016\/j.clim.2005.08.006_bib30","first-page":"30","article-title":"Chemotherapy sensitization by rituximab: experimental and clinical evidence","volume":"27","author":"Wilson","year":"2000","journal-title":"Semin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2005.08.006_bib31","first-page":"S1","article-title":"Mechanism of action of rituximab","volume":"12","author":"Maloney","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2005.08.006_bib32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","article-title":"Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis","volume":"28","author":"Vugmeyster","year":"2005","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.clim.2005.08.006_bib36","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.clim.2005.08.006_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"issue":"5A","key":"10.1016\/j.clim.2005.08.006_bib38","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab","volume":"20","author":"Alas","year":"2000","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol. Diseases"},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1073\/pnas.0437875100","article-title":"Variation in gene expression patterns in follicular lymphoma and the response to rituximab","volume":"100","author":"Bohen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.clim.2005.08.006_bib42","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration\u2013effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.08.006_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2005.08.006_bib45","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies","volume":"24","author":"Treon","year":"2001","journal-title":"J. Immunother."},{"issue":"12","key":"10.1016\/j.clim.2005.08.006_bib47","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","article-title":"CD20-mediated apoptosis: signalling through lipid rafts","volume":"107","author":"Deans","year":"2002","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib50","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","article-title":"Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains","volume":"104","author":"Bezombes","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib51","first-page":"2490","article-title":"Synergistic effects of the fenretinide (4-hpr) and anti-cd20 monoclonal antibodies on apoptosis induction of malignant human b cells","volume":"7","author":"Shan","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"6 Suppl. 12","key":"10.1016\/j.clim.2005.08.006_bib52","first-page":"37","article-title":"Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma","volume":"27","author":"McLaughlin","year":"2000","journal-title":"Semin. Oncol."},{"issue":"5 Suppl. 14","key":"10.1016\/j.clim.2005.08.006_bib53","first-page":"79","article-title":"Rituximab in indolent lymphoma: the single-agent pivotal trial","volume":"26","author":"McLaughlin","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.clim.2005.08.006_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000082103","article-title":"B lymphocyte depletion in rheumatoid arthritis: targeting of CD20","volume":"8","author":"Edwards","year":"2005","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.clim.2005.08.006_bib55","unstructured":"B. Davies, T. Shaw, Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide. Presented at EULAR, 2004."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/keh446","article-title":"Prospects for B-cell-targeted therapy in autoimmune disease","volume":"44","author":"Edwards","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF02982552","article-title":"Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody","volume":"74","author":"Maeda","year":"2001","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib59","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"9 Suppl.","key":"10.1016\/j.clim.2005.08.006_bib60","first-page":"S740","article-title":"A longitudinal analysis of SLE patients treated with rituximab: a comparison of B cell depleters to partial B cell depleters","volume":"52","author":"Dunham","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.clim.2005.08.006_bib62","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2005.08.006_bib63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF03165260","article-title":"Immune and cell therapy of hematologic malignancies","volume":"76","author":"Kipps","year":"2002","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1034\/j.1399-3089.2001.008003157.x","article-title":"Effects of specific anti-B and\/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody","volume":"8","author":"Alwayn","year":"2001","journal-title":"Xenotransplantation"},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib65","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ajcp\/112.6.844","article-title":"Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma","volume":"112","author":"Douglas","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib66","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174","volume":"5","author":"Bearden","year":"2005","journal-title":"Am. J. Transp."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","article-title":"Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)","volume":"98","author":"Gonzalez-Stawinski","year":"2001","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib69","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib70","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib71","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.clim.2005.08.006_bib72","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ni0901-764","article-title":"Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity","volume":"2","author":"Lipsky","year":"2001","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib73","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib74","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2005.08.006_bib75","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clim.2005.08.006_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"10.1016\/j.clim.2005.08.006_bib77","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D'Arcy","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.clim.2005.08.006_bib78","first-page":"S197","article-title":"Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis","volume":"46","author":"Edwards","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"25","key":"10.1016\/j.clim.2005.08.006_bib79","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.clim.2005.08.006_bib80","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0003-4967(24)43391-8","article-title":"Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab","volume":"60","author":"Stewart","year":"2001","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib82","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib83","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/sj.leu.2402588","article-title":"Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (rituximab) monotherapy","volume":"16","author":"Kelaidi","year":"2002","journal-title":"Leukemia"},{"issue":"6 Suppl. 12","key":"10.1016\/j.clim.2005.08.006_bib84","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib85","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2141.2001.02873-4.x","article-title":"Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)","volume":"114","author":"Ahrens","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib86","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2005.08.006_bib87","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2005.08.006_bib89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10428190109097770","article-title":"Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2001.03078.x","article-title":"Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease","volume":"115","author":"Berentsen","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.clim.2005.08.006_bib91","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2002.03278.x","article-title":"Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus","volume":"116","author":"Perrotta","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.clim.2005.08.006_bib92","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.clim.2005.08.006_bib93","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","article-title":"Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia","volume":"97","author":"Zecca","year":"2001","journal-title":"Blood"},{"issue":"9337","key":"10.1016\/j.clim.2005.08.006_bib94","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(03)00032-4","article-title":"B-cell depletion with rituximab\u2014A targeted therapy for Graves' disease and autoimmune thyroiditis","volume":"88","author":"Hasselbalch","year":"2003","journal-title":"Immunol. Lett."},{"issue":"8","key":"10.1016\/j.clim.2005.08.006_bib96","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"6781","key":"10.1016\/j.clim.2005.08.006_bib97","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.clim.2005.08.006_bib98","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.clim.2005.08.006_bib99","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI9244","article-title":"CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus","volume":"106","author":"Mihara","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.clim.2005.08.006_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex deposition","volume":"171","author":"Schiffer","year":"2003","journal-title":"J. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661605002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661605002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T11:00:00Z","timestamp":1735988400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661605002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1521661605002858"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2005.08.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}